- $1.64bn
- $1.43bn
- $892.08m
- 96
- 84
- 45
- 89
2019 October 31st | 2020 October 31st | 2021 October 31st | 2022 October 31st | 2023 October 31st | |
---|---|---|---|---|---|
Period Length: | 52 W | 52 W | 52 W | 52 W | 52 W |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 551 | 610 | 664 | 825 | 892 |
Cost of Revenue | |||||
Gross Profit | 121 | 135 | 167 | 294 | 336 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 499 | 546 | 569 | 613 | 639 |
Operating Profit | 52.1 | 63.9 | 94.6 | 212 | 253 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | 50.7 | 61.6 | 102 | 239 | 270 |
Provision for Income Taxes | |||||
Net Income After Taxes | 40.5 | 40.3 | 78.8 | 179 | 200 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 29.8 | 33.8 | 55.4 | 119 | 125 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 29.8 | 33.8 | 55.4 | 119 | 125 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.431 | 0.517 | 0.894 | 1.94 | 2.03 |